About Supernus Pharmaceuticals
Supernus Pharmaceuticals is a company based in Rockville (United States) founded in 2005. The company has 674 employees as of December 31, 2024. Supernus Pharmaceuticals has completed 3 acquisitions, including Adamas Pharma, Biscayne Pharma and SAGE Therapeutics. Supernus Pharmaceuticals offers products and services including QELBREE. Supernus Pharmaceuticals operates in a competitive market with competitors including Alto Neuroscience, Newron Pharmaceuticals, Neurovance, Seaport Therapeutics and Pasithea, among others.
- Headquarter Rockville, United States
- Employees 674 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Supernus Pharmaceuticals, Inc.
-
Annual Revenue
$661.82 M (USD)8.94as on Dec 31, 2024
-
Net Profit
$73.86 M (USD)5512.84as on Dec 31, 2024
-
EBITDA
$141.77 M (USD)44.28as on Dec 31, 2024
-
Latest Funding Round
$30 M (USD), Post-IPO
Jul 09, 2014
-
Investors
HealthCare Royalty Partners
& 1 more
-
Employee Count
674
as on Dec 31, 2024
-
Investments & Acquisitions
Adamas Pharma
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Supernus Pharmaceuticals
Supernus Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol SUPN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Supernus Pharmaceuticals
Supernus Pharmaceuticals offers a comprehensive portfolio of products and services, including QELBREE.
Approved treatment for central nervous system disorders
People of Supernus Pharmaceuticals
Unlock access to complete
Unlock access to complete
Sales and Marketing
160 people
Leadership Team
51 people
Product Management Team
14 people
Senior Team
14 people
Software Development Team
10 people
Operations Team
7 people
Finance and Accounting
7 people
Human Resources and Administration
5 people
Unlock access to complete
Funding Insights of Supernus Pharmaceuticals
Investors in Supernus Pharmaceuticals
Supernus Pharmaceuticals has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include HealthCare Royalty Partners and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare royalty investments are focused on US and UK markets.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Supernus Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Supernus Pharmaceuticals
Supernus Pharmaceuticals has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Adamas Pharma, Biscayne Pharma and SAGE Therapeutics.
Investment portfolio details for Supernus Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Clinical-stage drugs for CNS disorders and drug-resistant cancers are developed.
|
Locked | Locked | 2012 | Locked | |
|
Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics.
|
Locked | Locked | 2002 | Locked | |
|
Developer of drug candidates for the treatment of rare CNS disorders
|
Locked | Locked | 1971 | Locked |
Complete acquisition details for Supernus Pharmaceuticals
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Supernus Pharmaceuticals
Detailed financials for Supernus Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Supernus Pharmaceuticals Comparisons
Peer comparison for Supernus Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Supernus Pharmaceuticals
Supernus Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alto Neuroscience, Newron Pharmaceuticals, Neurovance, Seaport Therapeutics and Pasithea, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers
|
|
| Locked | Locked | Locked |
Therapies for central nervous system diseases and pain are developed.
|
|
| Locked | Locked | Locked |
Neurochemical modulators for ADHD treatment are developed by Neurovance.
|
|
| Locked | Locked | Locked |
Novel therapeutics for neuropsychiatric disorders are developed using proprietary technology.
|
|
| Locked | Locked | Locked |
Pasithea is focused on developing treatments for neurological disorders.
|
Detailed competitors of Supernus Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Supernus Pharmaceuticals
Complete news archive for Supernus Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Supernus Pharmaceuticals
Supernus Pharmaceuticals was founded in 2005 and raised its 1st funding round 7 years after it was founded.
Supernus Pharmaceuticals is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Jack Khattar is the current CEO of Supernus Pharmaceuticals.
As of Dec 31, 2024, the latest employee count at Supernus Pharmaceuticals is 674.
Annual revenue of Supernus Pharmaceuticals is $661.82M as on Dec 31, 2024.
Supernus Pharmaceuticals was founded in 2005 and is headquartered in Rockville, United States. Operations center on the development and commercialization of treatments for central nervous system diseases. Key products, such as Oxtellar and Trokendi, address epilepsy. The psychiatry pipeline features SPN-810 for impulsive aggression, SPN-812 for ADHD, and SPN-809 for depression. An acquisition of its parent company, Shrine Labs, occurred in late 2005.
Supernus Pharmaceuticals's top competitors include Alto Neuroscience, Newron Pharmaceuticals and Seaport Therapeutics.
Supernus Pharmaceuticals offers QELBREE.
Yes, Supernus Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol SUPN.
Supernus Pharmaceuticals has made 3 acquisitions, including Adamas Pharma, Biscayne Pharma, and SAGE Therapeutics.
Supernus Pharmaceuticals has 2 investors. Key investors include HealthCare Royalty Partners, and HHS.
The ticker symbol of Supernus Pharmaceuticals is SUPN on NASDAQ.